Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRIXADI vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
FDA-approved for the treatment of opioid use disorder (opioid dependence) as part of a comprehensive treatment plan
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Terminal half-life approximately 470–500 hours (~20 days) following intramuscular injection, allowing weekly or monthly dosing.
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Primarily metabolized by CYP3A4 to norbuprenorphine (active metabolite) via N-dealkylation; also undergoes glucuronidation.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Primarily fecal (80–90%) as unchanged drug; renal elimination accounts for <5% of the dose.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
Approximately 99% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
30-35% bound to albumin.
Volume of distribution is very large, approximately 500–1000 L (about 5–10 L/kg in a 70 kg individual), indicating extensive tissue binding and sequestration.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Intramuscular injection: bioavailability is nearly 100% due to limited first-pass metabolism; oral bioavailability is <5% due to extensive first-pass metabolism.
Oral: 70-85% with high variability; intrathecal: 100%.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease, use with caution and consider dose reduction due to potential accumulation; specific dosing guidelines not established.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Child-Pugh Class A (mild): No adjustment. Child-Pugh Class B (moderate): Start at lower dose and titrate cautiously; maximum recommended weekly dose 16 mg, monthly dose 96 mg. Child-Pugh Class C (severe): Not recommended due to lack of data.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Not approved for use in pediatric patients; safety and efficacy not established.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
No specific dose adjustments recommended; geriatric patients may have increased sensitivity and should be monitored closely for sedation, respiratory depression, and QTc prolongation. Initiate at lower end of dosing range if severe renal or hepatic impairment present.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of harm or death from accidental ingestion; concomitant use of benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
May cause respiratory depression; risk of abuse potential; need to monitor for hepatic dysfunction; adrenal insufficiency; QT prolongation; precipitation of withdrawal if initiated too soon after full agonist opioids; impairment of mental/physical abilities.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 14 days.
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
No specific food interactions are reported for BRIXADI. However, patients should avoid alcohol and grapefruit juice as they may potentiate CNS depression or alter metabolism (grapefruit inhibits CYP3A4, which metabolizes buprenorphine, potentially increasing levels). Advise a balanced diet without restrictions beyond general health recommendations.
No specific food interactions. Avoid alcohol due to additive CNS depression.
Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Unknown if excreted in human milk; no M/P ratio available. Consider risks and benefits; avoid breastfeeding if possible.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
No standard dose adjustment; increased clearance in pregnancy may require dose titration to effect. Monitor for withdrawal or inadequate response.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
BRIXADI (buprenorphine extended-release) is a monthly subcutaneous depot formulation for opioid use disorder (OUD). Initiate only after patient is stabilized on transmucosal buprenorphine (e.g., 8–24 mg/day for at least 7 days). Do not use in opioid-naive patients due to risk of precipitated withdrawal. Administer subcutaneously in the abdomen; avoid intramuscular or intravenous injection. Monitor injection site for nodules, granulomas, or infection. Concomitant use with benzodiazepines or CNS depressants requires careful monitoring due to additive respiratory depression. Liver function tests should be monitored periodically due to risk of hepatic injury. BRIXADI contains buprenorphine as the free base, not salt; dose strengths (64 mg, 96 mg, 128 mg) are not equivalent to other buprenorphine formulations. Upon discontinuation, patients may experience prolonged withdrawal due to slow release over weeks.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
BRIXADI is a once-monthly injection to treat opioid dependence and must be given by a healthcare provider only.,Do not attempt to self-administer or remove the injection. The medicine is released slowly over one month.,Notify your doctor immediately if you have trouble breathing, excessive drowsiness, or severe dizziness, especially when combined with alcohol or sedatives.,Avoid use of other opioids (prescription or illicit), as serious side effects including coma or death may occur.,Report any signs of liver problems: dark urine, yellowing skin/eyes, persistent nausea, or abdominal pain.,The injection site may become red, swollen, or painful; contact your doctor if these persist or worsen.,Do not stop BRIXADI suddenly; withdrawal symptoms may occur and can be prolonged.,Keep out of reach of children and pets; accidental exposure can be fatal.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRIXADI vs BACLOFEN, answered by our medical review team.
BRIXADI is a Opioid Partial Agonist that works by Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRIXADI and BACLOFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRIXADI is: Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRIXADI and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRIXADI is classified as Category C. Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.